The surge in shoulder implants along with the number of sports-related injuries is one of the reasons for this growing need of implants among patients, and a company that successfully addresses such requirements is FX Shoulder USA.
Founded in the beginning of 2018, FX Shoulder is focusing exclusively on shoulder arthroplasty. A subsidiary of French-based FX Solutions S.A.S, FX Shoulder was established to render unique and innovative shoulder implants to the existing and future customers in the US. As a growing company, FX Shoulder works with surgeons and engineers to continuously evolve, and expand upon, its existing comprehensive portfolio by producing innovative solutions designed for specific and complex cases.
Blending Knowledge and Experience
FX Shoulder was formed as an exclusive provider of FX Solutions’ products, and ever since it has collaborated with many distributors as well as surgeons. Surgeons that use the FX Shoulder portfolio further share their expertise with new, potential surgeons and/or distributors alike. “The surgeon-instructed training for the distributors and sales representatives is key to our continued growth. We want knowledgeable and experienced professionals who can properly present and provide our products,” mentions Baptiste Martin, CEO, FX Shoulder. These efforts have produced excellent opportunities for the firm to acquire new customers.
As a small, growing company, FX Shoulder participates in several exhibitions (for example the AAOS 2019 in Las Vegas, Nevada (booth 3431) which gives them tremendous exposure to market their portfolio of shoulder implants to surgeons who might be interested in using their products. In order to continuously evolve, refine its strategy, and stay relevant, it is important for a company to have a team with a shared vision. The FX Shoulder team has a collective vision to assure a best fit for the requirements of the current marketplace, and continuously redefine and further develop their strategy and portfolio.
FX Shoulder offers a comprehensive portfolio of solutions for degenerative and trauma-based cases with the goal of improving patient care. FX Shoulder has FDA clearance for its portfolio of shoulder arthroplasty that includes the Humelock II®, an interlocking stem as an anatomic and reversible process for traumatic shoulder injuries, which eliminates the need for using cement in the surgery and the stress of managing the height and version. The company promotes the usage of screws in shoulder arthroplasty surgeries; but the surgeons who are not comfortable with screws have the option of a cemented stem as well. The inter, locking stem offered by the parent company, FX Solution’s is well accepted in Europe and was introduced in the US in 2016.
As a complement to the system, the Humelock Reversed®—a reverse shoulder implant with a locking stem— is used to treat both degenerative as well as trauma-related injuries. The locking stem allows surgeons to treat 3 or 4 part fractures of the proximal humerus. The Humelock Reversed® has its resection at 145° and a 3.5mm lateralized glenosphere that allow a good deltoid tensioning as well as a great stability.
FX offers a comprehensive portfolio of solutions on shoulder arthroplasty (only the shoulder) for degenerative and trauma-based cases with the vision to improve patient care
Additionally, with a vision toward the future, FX Shoulder seeks to bring the existing stemless prosthesis that is available in Europe to the US Market. This innovative implant that FX offers could potentially reduce the time of surgery—and while it is not approved in the US yet, FX Shoulder is looking forward to beginning a clinical study of the stemless implant for the reverse process in the US soon, which will be FX Shoulder’s first clinical study in the country. The Easytech® stemless shoulder prosthesis has been used in Europe since 2015. “The Easytech Reversed is exactly what the U.S. market is in need of. And, reverse stemless prosthesis could potentially be the future of shoulder arthroplasty,” said Baptiste. “We are excited to begin our clinical study and eager to see the results with each successive case throughout. There is a lot of excitement for Easytech Reversed,” he continued to say. In Europe, FX Solutions has implanted 867 Easytech Stemless Reversed prosthesis to date and, as per the article in Med Device Online dated April 11, 2018, stemless implants are projected to surpass stemmed implants by 2025 (in Europe).
The industry as well as FX Shoulder continues to embrace new technologies to address the needs of specific complex cases with the goal of reproducing good outcomes from one patient to the another. Baptiste sees tremendous opportunities in the shoulder arthroplasty landscape and believes it’s an exciting time to be in this sector considering the emergence of revision surgeries. Thus, FX Shoulder is working toward introducing revision shoulder arthroplasty systems. In addition to the stemless system, the company has several projects in the pipeline. New products will focus on implants to improve patients’ outcomes. “As we continue to grow our footprint, we will also develop and redefine our focus on new target markets and any potential opportunities that arise in the process,” concludes Baptiste.